Prospective observational study to identify efficacy of induction treatments consist of bortezomib-lenalidomide-dexamethasone in transplant-eligible newly diagnosed multiple myeloma
Not Applicable
Recruiting
- Conditions
- Neoplasms
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 250
Inclusion Criteria
1)Patients over 19 years old
2)Patients diagnosed with multiple myeloma in need of treatment
3)Patients planning VRD combination therapy and subsequent autologous hematopoietic stem cell transplantation according to ITT's plan
Exclusion Criteria
1) Neutrophil count <1,000/mm3 at the time of study registration
2) Platelet count <80,000/mm3 at the time of study registration
3) a pregnant woman or a lactating woman
Study & Design
- Study Type
- Observational Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Minimal Residual Disease
- Secondary Outcome Measures
Name Time Method Progression - free survival
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie VRD (bortezomib-lenalidomide-dexamethasone) efficacy in transplant-eligible multiple myeloma patients?
How does VRD induction therapy compare to standard-of-care regimens like RVD in newly diagnosed multiple myeloma outcomes?
Which biomarkers correlate with response to VRD in multiple myeloma, particularly in high-risk cytogenetic subtypes?
What are the most common adverse events associated with VRD induction in transplant-eligible multiple myeloma patients?
How do VRD-based combinations compare to other proteasome inhibitor-IMiD-dexamethasone regimens in multiple myeloma treatment?